Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (May 2005)
21 slides from Resonance Health's investor presentation, May 2005
Slide 1: Commercialising the FerriScan Technology: The Future of Liver Diagnosis
Commercialising the FerriScan™ Technology “The Future of Liver Diagnosis” Investor Update May 2005 1
Slide 2: Resonance Health Limited (ASX:RHT)
Resonance Health Limited (ASX:RHT) • Resonance Health is a Healthcare service provider positioned for growth – Key Regulatory clearances for lead product (FerriScan) (US, Europe, Australia). – Significant strategic alliances established (DCA Group, Novartis), others imminent. – Initial sales of Ferr
Slide 3: What is the FerriScan technology?
What is the FerriScan technology? • A safe, non-invasive and accurate test to measure liver iron concentration • Utilises existing MRI equipment, proprietary software and a patented iron “marker” known as “R2” • Provides clinicians around the world with a new and safe diagnostic tool to track liver
Slide 4: Why Test for Iron Overload?
Why Test for Iron Overload? • Chronic disorders of iron metabolism are among the most common genetic diseases – Conditions include: heamochromatosis and haemoglobinopathies – More that 10 million people affected globally • Excess iron accumulates in the body and, if left untreated, is a major cause
Slide 5: Distribution Map – Iron Overload Disorders
Distribution Map – Iron Overload Disorders 4,000,000 10,000,000 100,000 5
Slide 6: FerriScan Has The Potential To Reduce Cost & Improve Patient Care
FerriScan Has The Potential To Reduce Cost & Improve Patient Care Providers / Reduced cost of care Reimbursement Groups Improve patient monitoring and safety Only a liver biopsy provides direct information on possible contributions of iron to the progression of iron overload A Liver Biopsy is the di
Slide 7: FerriScan service delivery
FerriScan service delivery •No new equipment purchases required at radiology centre – standard MRI instruments •MRI images processed at RHT Analysis Centre using IVB proprietary software, optimising quality control and security of the technology 7
Slide 8: FerriScan: Iron overload - USA & Australian Market Potential
FerriScan: Iron overload - USA & Australian Market Potential Australia USA Total Market: genetic 125,000 2,000,000 predisposition for iron overload Addressable Market: Clinically 33,000 750,000 significant iron overload Potential FerriScan™ service fee $250 - $350 $250 - $450 (AUD)* Addressable mark
Slide 9: Indicative Model of Potential Gross Profit
Indicative Model of Potential Gross Profit Based on %US / Aus Potential Revenue 1 Potential Test Numbers Addressable Gross Profit @ Market 65% GM 20,000 2.5% $6M $3.9M 40,000 5% $12M $7.8M 60,000 7.5% $18M $11.7M 100,000 2 12.5% $30M $19.5M Note: 1 At average revenue of AUD$300 per test 2 < 4 scans
Slide 10: FerriScan: Roll-out strategy
FerriScan: Roll-out strategy Primary distribution channel • Diagnostic imaging groups – Australia: DCA Group – UK: MedTel and DCA Group – US: Major US chain(s) (100+ installed MRI sites – largest have 300+) Secondary channels • Service provision to clinical trials – Pharmaceutical companies: e.g. Ex
Slide 11: FerriScan: Roll-out schedule
FerriScan: Roll-out schedule Australia • Trial marketing commenced (April) • Launched to key physicians in WA, SA, Queensland and Tasmania • First sales achieved / referrals made • Victoria and NSW currently being activated • Expanded roll-out second half 2005 US • Imaging company discussions at lat
Slide 12: Resonance Health – a global diagnostic service provider with medical device margins
Resonance Health – a global diagnostic service provider with medical device margins IVB is uniquely positioned as a Diagnostic/Theranostic Service Medical Devices European Diagnostic: Australian Device: Innogenetics; Australian: Sirtex BioPredictive CompuMedics; ResMed USA: Health Services MedicSigh
Slide 13: Benchmark examples of Diagnostic Imaging companies
Benchmark examples of Diagnostic Imaging companies Medical Device Medical IT Solution Diagnostic Service Company Description Mkt Cap: Cash: Status MedicSight Medicsight is a medical imaging software company. Its core MC: US$165m FDA approvals for three products (USA) technology is focused on develop
Slide 14: Resonance Health – New Board Members
Resonance Health – New Board Members Mr Ian Anderson (48) – Non-Executive Director BBus (ECU) MBA (UWA) Mr Anderson is currently on secondement to the North Metropolitan Area Health Service of Western Australia as Area Executive Director, Finance & Corporate Services. Prior to this, Mr Anderson was
Slide 15: Resonance Health – New Board Members
Resonance Health – New Board Members Dr Jay Ives (49) - Non-Executive Director MB ChB (Otago) FRANZCR Dr Ives is a former partner and member of the Executive Committee of SKG Radiology (prior to its sale to Sonic Healthcare Ltd), and continues in his role as Technical Director for the practice. Dr I
Slide 16: Resonance Health – New Board Members
Resonance Health – New Board Members Dr James Williams (35) – Managing Director BSc (Hons) (Aberdeen) PhD (Melbourne) MBA (UWA) Dr Williams has a track record of establishing health technology companies, with origins in academic institutions, and rapid progression of their products to market. Dr Wil
Slide 17: Operational Management
Operational Management • Glenn Smith, BA/BEcon MBA, Marketing Director – Prior roles include CEO, Tri-Med responsible for rolling out multiple diagnostic product lines to over 30 countries – Marketing leader responsible for establishing an e-commerce, telemedicine project and service line generating
Slide 18: RHT capital structure
RHT capital structure (As at 31 March 2005) Shares on issue: Currently on issue and listed (RHT) 111,353,585 Proposed issue of ordinary shares to IVB shareholders 68,140,438 Total shares on issue – all classes 189,494,023 Market Capitalisation at 30 May 2005 closing ($0.14) $26.5 million Performance
Slide 19: Resonance Health: Positioned for growth
Resonance Health: Positioned for growth 1. Key regulatory clearances achieved (Australia, US and Europe) 2. Significant partnerships established (DCA Group, MedTel and Novartis). Others pending. 3. Initial commercial sales achieved in both Australia and internationally through partners 4. Research p
Slide 20: Forward looking statements and risks
Forward looking statements and risks This presentation contains forward-looking statements that are based on management’s current expectations. These statements may differ materially from actual future events or results due to the range of risks and uncertainties associated with the healthcare techn
Slide 21: Contact Details
Contact Details Dr James Williams, Managing Director Resonance Health Ltd ABN 96 006 762 492 First Floor, 216 Stirling Highway, Claremont Western Australia 6010 Tel +61 8 9286 5300 Fax +61 8 9286 5399 www.resonancehealth.com www.ferriscan.com Tony Fitzgerald, Executive Director Resonance Health Ltd